The Latest Breaking News from Obesity

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro (one of the brand names for tirzepatide).

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Experts have weighed in as long waiting lists for care are sending more people overseas for help

Poor diet, obesity and inactivity blamed on decline with Norway the only country seeing a rise

Experts have published new guidance on best practice for travelling abroad for care.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol

Company will give up to 20% off treatments such as Wegovy and Mounjaro through private cover

Weight bias is pervasive in medical settings, say experts.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast